Apogee Therapeutics Reported Q2 Net Loss Of $(33.8)M Vs $(18.9)M YoY, Cash Balance Of $789.6M With Runway Into 2028
Portfolio Pulse from Benzinga Newsdesk
Apogee Therapeutics reported a Q2 net loss of $33.8 million, up from $18.9 million YoY. The company has a cash balance of $789.6 million, expected to fund operations into 2028.
August 12, 2024 | 10:37 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apogee Therapeutics reported a significant increase in net loss for Q2 2024 compared to the previous year, but maintains a strong cash position expected to fund operations into 2028.
The significant increase in net loss may concern investors, potentially leading to a short-term negative impact on the stock price. However, the strong cash position provides a buffer, mitigating some concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100